The evaluation of microhaematuria may be considered as a measure of the haemostatic defect of haemophiliacs in nonhaemorrhagic periods. In order to study the relationship between coagulation disorder and haemostatic defect we have administered small amounts (1 U and 3 U/kg) of AHG and of factor IX (1 U/kg) to 12 haemophiliacs (10 A and 2 B) and we have examined the effects on coagulation and microhaematuria. Microhaematuria was determined by the measurement of urinary radioactivity/24 h, after infusion of autologous RBC labelled with 51Cr, for 11 consecutive days (4 days before and 7 after the administration). Coagulation was investigated by thromboelastography, PTT, Quick’s time, PCI, factor VIII and IX activity assays, fibrinogen assay, and euglobulin lysis time. During the period of investigation, the patients remained in bed. In controls, factor VIII administration did not affect microhaematuria. On the other hand, in all haemophiliacs, factor VIII and IX administration significantly reduced microhaematuria, although the administered dose was not able to modify the coagulation defect. In all subjects the reduction of microhaematuria lasted at least 5 days. The correction of the haemostatic defect, without improvement of the clotting disorder, and its persistence for several days suggest that factor VIII is involved in the composition of the vascular wall and in its functional integrity. Moreover, on the basis of these results it is possible to carry out a rational prophylaxis of the haemorrhagic episodes using small doses of factor VIII, by determining the duration of the correction of the haemostatic defect for each subject.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.